How to dose and monitor ACE inhibitors in HF patients in primary care?

Appropriate dosing of ACE inhibitors (ACEi) in heart failure managed in primary care involves starting at a low dose and gradually titrating upwards at short intervals (e.g., every 2 weeks) to reach the target or maximum tolerated dose based on the patient's clinical response and tolerability. This gradual titration should be accompanied by close monitoring of renal function (serum sodium, potassium, and creatinine), blood pressure, and signs of intolerance before and 1 to 2 weeks after initiation, and after each dose increment. Blood pressure measurements should include assessment for postural hypotension according to hypertension guidelines.

For example, in heart failure, initial doses of ACEi like captopril should start low (e.g., 6.25–12.5 mg two or three times daily) and titrated every two weeks up to the maintenance target dose (75–150 mg per day), with dose adjustments made according to blood pressure, renal function, and potassium levels. Similar titration principles apply to other ACEi agents prescribed in primary care.

Once the target or maximum tolerated dose is reached, ongoing monitoring should be monthly for the first three months and then at least every six months, and upon any acute illness. Monitoring includes renal function tests (serum sodium, potassium, creatinine) and blood pressure assessments, with prompt evaluation if the patient becomes acutely unwell.

In patients with heart failure and chronic kidney disease (eGFR ≤45 ml/min/1.73 m2), lower starting doses and/or slower titration should be considered due to heightened risk of hyperkalaemia and renal impairment.

Monitoring should also address hyperkalaemia risks, with strategies to maintain ACEi therapy where possible, as down-titration or discontinuation should be a last resort after other interventions and specialist advice. Patient education on the importance of ACEi therapy and management of hyperkalaemia is essential.

In practice, structured transitional care interventions from hospital to primary care, including medication titration plans communicated to general practitioners, significantly improve adherence to target doses of ACEi and other guideline-directed medical therapies during the critical post-discharge period.